Skip to main content
Signal8

Lunai Bioworks Inc. (LNAI)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Lunai Bioworks Inc. logo

Lunai Bioworks Inc.

OTC:LNAIOTC (delisted from Nasdaq, Form 25 effective Nov 12, 2026)Healthcare
Mkt Cap$830K
EV-
Float4.88M
O/S5.03M
VOL1.27M sh
$ Vol$195K
RVOL0.86×
Inst Own3.8%
SI0.4%
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Oct 29, 20260.22900.23000.14100.16481,275,391
Oct 28, 20260.22110.25000.20230.2361622,776
Oct 27, 20260.25760.26990.24030.2525521,332
Oct 26, 20260.26290.30160.23270.2750620,807
Oct 23, 20260.26000.31560.22650.29469,584,097
Oct 22, 20260.53000.53000.46010.4700174,309
Oct 21, 20260.49950.54450.49950.518090,439
Oct 20, 20260.49000.57980.47200.5150218,625
Oct 19, 20260.69520.69520.46150.4720205,222
Oct 16, 20260.81220.81220.66020.680479,860
Oct 15, 20260.86540.91720.81770.825537,877
Oct 14, 20260.99911.010.89220.892269,619
Oct 13, 20261.091.091.011.0350,362
Oct 12, 20261.291.291.051.1197,191
Oct 9, 20261.171.680.87571.23858,870
Oct 8, 20261.141.151.101.1214,852
Oct 7, 20261.191.191.081.0919,979
Oct 6, 20261.131.201.131.1323,645
Oct 5, 20261.251.301.141.1469,260
Oct 2, 20261.441.461.231.30124,972
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
3.8%
Institutional
(17)
0.1%
Insiderⓘ
(2)
16.5%
5%+ Owners
(4)
of which 6.5% rests on schedules older than 24 months (2 holders)
79.6%
Unattributed (incl. retail)ⓘ
Institutional3.8%
Insider0.1%
5%+ Beneficial16.5%
Unattributed (incl. retail)79.6%
Top Shareholders
NameShares%
Laksya Ventures Inc. logo
Laksya Ventures Inc.
· may incl. warrants· filed Sep 2025
277.1K5.5%
William Anderson Wittekind logo
William Anderson Wittekind
· may incl. warrants· filed Oct 2026
226.7K4.5%
Rene Sindlev logo
Rene Sindlev
· may incl. warrants· stale · filed Feb 2024
186.8K3.7%
Paseco ApS logo
Paseco ApS
· may incl. warrants· stale · filed Feb 2024
139.5K2.8%
VANGUARD CAPITAL MANAGEMENT LLC logo
VANGUARD CAPITAL MANAGEMENT LLC
50.0K1.0%
GEODE CAPITAL MANAGEMENT, LLC logo
GEODE CAPITAL MANAGEMENT, LLC
41.5K0.8%
STATE STREET CORP logo
STATE STREET CORP
37.5K0.7%
JANE STREET GROUP, LLC logo
JANE STREET GROUP, LLC
21.6K0.4%
BlackRock, Inc. logo
BlackRock, Inc.
15.9K0.3%
UBS Group AG logo
UBS Group AG
12.2K0.2%
Sources: 13F, Form 4, 13D/13GO/S: 5.0M · as of 13 Oct 2026 · SEC filings
Insiders & Institutional Holders
About

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

Key Metrics
Market Cap$829,678
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership3.79%

based on 5.03M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateSep 30, 2025
Shares Outstanding5.03M
Authorized Shares
Float4.88M
SEC Float (non-affiliate)4.97M
52-Week Range
Volume
Average Daily Volume1.48M

30d Avg

1.48M

60d Avg

529.20K

90d Avg

320.68K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of LNAI as of Jun 30, 2026 records 3 outstanding warrant series and an offering priced Sep 2, 2026, from SEC filings. Lunai Bioworks Inc. (OTC: LNAI) is in the Healthcare sector (Biotechnology).